Epitope-Driven Polyfunctional Divergence of SARS-CoV-2 RBD Antibodies
Pierre RosenbaumiD, Cyril PlanchaisiD, Timothée BrueliD, Maxime BerettaiD, Isabelle StaropoliiD, William BollandiD, Florence Guivel‐BenhassineiD, Delphine PlanasiD, French COVID Cohort Study Group, CORSER Study Group, Olivier SchwartziD, Hugo MouquetiD
Abstract
SARS-CoV-2 antibodies targeting the receptor binding domain (RBD) of the spike protein can potently neutralize infection and exert additional antiviral functions. Here, we characterize the functional profiles of human RBD-specific memory B-cell antibodies elicited by ancestral SARS-CoV-2 infection. While SARS-CoV2 neutralizing antibodies, mainly class 1 and 3 anti-RBD antibodies, often lose binding and neutralizing capacities against Omicron variants, most non-neutralizers remain broadly reactive. Despite their restricted cross-reactivity, neutralizing antibodies mediate Fc-effector functions including antibody-dependent cellular cytotoxicity, phagocytosis, and complement deposition. Most neutralizers also enhance binding of antibodies that target the SARS-CoV-2 spike fusion peptide via receptor-mimetic allostery. In contrast, broadly reactive non-neutralizers fail to trigger phagocytic or allosteric effects. Thus, viral escape compromises antibody neutralizing as well as other antiviral activities, leaving broadly reactive, non-polyfunctional antibodies that exert minimal immune pressure less effective at controlling infection.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- FWCI
- 0.00
- Field percentile
- 0th percentile
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Delineating the functional activity of antibodies with cross-reactivity to SARS-CoV-2, SARS-CoV-1 and related sarbecoviruses
Felicitas Ruiz, William B. Foreman, … Julie M. Overbaugh·PLoS PathogensPeer-reviewed·Oct 28, 2024
- Conserved Neutralizing Epitopes on the N-Terminal Domain of Variant SARS-CoV-2 Spike Proteins
Z. Wang, F. Muecksch, … M. C. Nussenzweig·bioRxiv·Feb 1, 2022
- Impact of the B.1.1.7 variant on neutralizing monoclonal antibodies recognizing diverse epitopes on SARS-CoV-2 Spike
C. Graham, J. Seow, … K. J. Doores·bioRxiv·Feb 3, 2021
- Antibodies that neutralize all current SARS-CoV-2 variants of concern by conformational locking
L. Liu, R. G. Casner, … D. D. Ho·bioRxiv·Apr 8, 2023
- Protective effect and molecular mechanisms of human non-neutralizing cross-reactive spike antibodies elicited by SARS-CoV-2 mRNA vaccination
Jordan J. Clark, Irene Hoxie, … Florian Krammer·Cell ReportsPeer-reviewed·Nov 1, 2024
- Potent human neutralizing antibodies elicited by SARS-CoV-2 infection